Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 14;17(2):250.
doi: 10.3390/cancers17020250.

A Retrospective, Single-Center Study Comparing Neoadjuvant ACTHP vs. DCbHP in HER2-Positive Early Breast Cancer Patients

Amit Itay  1 , Opher Globus  1 , Keren Levanon  1   2 , Tal Sella  1 , Rinat Bernstein-Molho  1 , Tal Shapira  1 , Cecilie Oedegaard  1 , Dana Fourey  1 , Einav Nili Gal Yam  1   2
Affiliations

A Retrospective, Single-Center Study Comparing Neoadjuvant ACTHP vs. DCbHP in HER2-Positive Early Breast Cancer Patients

Amit Itay et al. Cancers (Basel). .

Abstract

Background: Neoadjuvant systemic therapy is the preferred treatment approach for stage II-III HER2-positive breast cancer (BC). Real-life data comparing regimens with or without anthracyclines combined with two HER2 drugs is lacking. We compared the efficacy and toxicity of two commonly used regimens.

Methods: Retrospective data were collected on patients newly diagnosed with clinical stage II-III HER2-positive BC and treated at Sheba Medical Center, Israel, between September 2017 and June 2022 with either neoadjuvant DCbHP (docetaxel, carboplatin, trastuzumab, pertuzumab) or ACTHP (doxorubicin, cyclophosphamide, paclitaxel trastuzumab pertuzumab). PCR (pathological complete response) (ypT0/isN0) was evaluated in both cohorts and according to HER2 immunohistochemistry (IHC) staining (3+ or 2+ and fluorescence in situ hybridization [FISH] positive), estrogen receptor (ER), tumor size and nodal status. The toxicity indices evaluated were reductions in left ventricle ejection fraction (LVEF), dose reductions, hospitalizations and febrile neutropenia.

Results: Here, 106 received ACTHP and 73 received DCbHP. Median age at diagnosis, ER status, HER2 IHC (2+/FISH pos or 3+) and nodal status were balanced. PCR occurred in 63.1% of patients, 67.0% and 57.5% in the ACTHP and DCbHP groups, respectively (p = 0.129). In patients with HER2 3+ IHC, pCR rates were significantly better with the ACTHP regimen than with DCbHP (83% vs. 62.9%, p < 0.039). No difference was observed among patients with HER2 +2 IHC FISH pos. Symptomatic LVEF decrease was observed in seven patients (6.6%) receiving ACTHP vs. none (0%) receiving DCbHP (p < 0.001).

Conclusions: PCR rates were similar overall between ACTHP and DCbHP; however, in the HER2 3+ subgroup, ACTHP demonstrated increased efficacy. DCbHP was significantly less cardiotoxic.

Keywords: Her-2 positive; anthracyclines; breast cancer; cardiotoxicity; congestive heart failure; early breast cancer; neoadjuvant therapy; pathologic complete response.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Untch M., Fasching P.A., Konecny G.E., Hasmüller S., Lebeau A., Kreienberg R., Camara O., Müller V., du Bois A., Kühn T., et al. Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results from the TECHNO Trial of the AGO and GBG Study Groups. J. Clin. Oncol. 2011;29:3351–3357. doi: 10.1200/JCO.2010.31.4930. - DOI - PubMed
    1. Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Bonnefoi H., Cameron D., Gianni L., Valagussa P., et al. Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. Lancet. 2014;384:164–172. doi: 10.1016/S0140-6736(13)62422-8. - DOI - PubMed
    1. Seidman A., Hudis C., Pierri M.K., Shak S., Paton V., Ashby M., Murphy M., Stewart S.J., Keefe D. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. J. Clin. Oncol. 2002;20:1215–1221. doi: 10.1200/JCO.2002.20.5.1215. - DOI - PubMed
    1. Moja L., Tagliabue L., Balduzzi S., Parmelli E., Pistotti V., Guarneri V., D’Amico R. Trastuzumab Containing Regimens for Early Breast Cancer. Cochrane Database Syst. Rev. 2012:1–65. doi: 10.1002/14651858.CD006243.pub2. - DOI - PMC - PubMed
    1. Bowles E.J.A., Wellman R., Feigelson H.S., Onitilo A.A., Freedman A.N., Delate T., Allen L.A., Nekhlyudov L., Goddard K.A.B., Davis R.L., et al. Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study. JNCI J. Natl. Cancer Inst. 2012;104:1293–1305. doi: 10.1093/jnci/djs317. - DOI - PMC - PubMed

LinkOut - more resources